Replikun Biotech’s Kunjin replicon technology can be used for the development of a wide range of immunotherapies. Applications include:

• Vaccine development
• Immunotherapy development
• Therapeutic protein production

Replikun's vaccines are built on the persistent, self-amplifying Kunjin replicon. The company's development programs in vaccines and immunotherapeutics have lead to product opportunities in the infectious diesase and oncology sectors. Replikun's programs are currently being advanced internally and are in preclinical development.

Replikun is seeking development opportunities with groups that are able to bring the appropriate skills and resources to the Kunjin Replicon technology and take advantage of the long patent term available. The technology is protected by four patent families, which extend product and manufacturing protections as far as 2026.

For further information on collaboration or licensing opportunities please contact:

Back to top